Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Continuous infusion therapy in haemophilia

D Varon1, U Martinowitz

  • 1National Haemophilia Center, Sheba Medical Center, Tel Hashomer, Israel. dvaron@trendline.co.il

Haemophilia : the Official Journal of the World Federation of Hemophilia
|January 5, 1999
PubMed
Summary

Continuous infusion (CI) of coagulation factors offers a stable haemostatic effect, superior to bolus injection (BI). This method is effective for hemophilia A and B, patients with inhibitors, and von Willebrand disease, while also reducing factor concentrate requirements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A New Class of Antiarrhythmic-Defibrillatory Compounds.

Journal of basic and clinical physiology and pharmacology·2025
Same author

Impact of frailty on outcomes in surgical patients: A systematic review and meta-analysis.

American journal of surgery·2018
Same author

Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.

European journal of internal medicine·2016
Same author

Current strategy for genetic analysis of haemophilia A families.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The fixed flexed and subluxed knee in the haemophilic child: what should be done?

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Area of Science:

  • Hematology
  • Pharmacology
  • Medical Devices

Background:

  • Continuous infusion (CI) of coagulation factors was proposed in the 1950s.
  • Recent advancements in factor concentrate stability, safety, and delivery systems have enabled its practical application.
  • Improved understanding of factor concentrate pharmacokinetics is crucial.

Purpose of the Study:

  • To evaluate the efficacy and benefits of continuous infusion (CI) compared to bolus injection (BI) for coagulation factor therapy.
  • To assess the effectiveness of CI in various bleeding disorders and patient populations.

Main Methods:

  • Review of historical data and recent clinical developments in coagulation factor therapy.
  • Comparison of continuous infusion (CI) versus bolus injection (BI) based on haemostatic stability and clinical outcomes.

Related Experiment Videos

  • Assessment of factor concentrate stability, safety, and pharmacokinetic profiles.

    • Main Results:

    • Continuous infusion (CI) provides a more stable haemostatic effect than bolus injection (BI).
    • CI is effective in preventing post-operative bleeding.
    • This therapy can reduce the required amount of factor concentrate by 20-50%.

    Conclusions:

    • Continuous infusion (CI) is a superior method for coagulation factor therapy compared to bolus injection (BI).
    • CI demonstrates efficacy in hemophilia A and B, patients with Factor VIII inhibitors, and von Willebrand disease (vWD).
    • The stability and safety of modern factor concentrates support the widespread adoption of CI.